Targeting TLR2 attenuates pulmonary inflammation and fibrosis by reversion of suppressive immune microenvironment

Journal of Immunology

Volumn 182, Issue 1, 2009, Pages 692-702

  Yang, Hong Zhen ^a   Cui, Bing ^a   Liu, Han Zhi ^a   Chen, Zhi Rong ^a   Yan, Hui Min ^a   Hua, Fang ^a   Hu, Zhuo Wei ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; TOLL LIKE RECEPTOR 2; AUTACOID; IMMUNOSUPPRESSIVE AGENT; TLR2 PROTEIN, MOUSE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; LUNG FIBROSIS; LUNG INJURY; MALE; MICROENVIRONMENT; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; CELL MOTION; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENDOTRACHEAL INTUBATION; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; TH1 CELL;

ANIMALS; BLEOMYCIN; CELL DIFFERENTIATION; CELL MOVEMENT; CELLS, CULTURED; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; INTUBATION, INTRATRACHEAL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PULMONARY FIBROSIS; TH1 CELLS; TOLL-LIKE RECEPTOR 2;

EID: 59849084848     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.182.1.692     Document Type: Article

References (41)

1. Aoki, F., M. Kurabayashi, Y. Hasegawa, and I. Kojima. 2005. Attenuation of bleomycin-induced pulmonary fibrosis by follistatin. Am. J. Respir. Crit. Care Med. 172: 713-720.
2. Meneghin, A., and C. M. Hogaboam. 2007. Infectious disease, the innate immune response, and fibrosis. J. Clin. Invest. 117: 530-538.
3. Brown, K. K., and G. Raghu. 2004. Medical treatment for pulmonary fibrosis: current trends, concepts, and prospects. Clin. Chest. Med. 25: 759-772.
4. Thannickal, V. J., G. B. Toews, E. S. White, J. P. Lynch Iii, and F. J. Martinez. 2004. Mechanisms of pulmonary fibrosis. Annu. Rev. Med. 55: 395-417.
5. Wynn, T. A. 2004. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat. Rev. Immunol. 4: 583-594.
6. Strieter, R., and M. Keane. 2004. Innate immunity dictates cytokine polarization relevant to the development of pulmonary fibrosis. J. Clin. Invest. 114: 165-168.
7. Kim, K. K., M. C. Kugler, P. J. Wolters, L. Robillard, M. G. Galvez, A. N. Brumwell, D. Sheppard, and H. A. Chapman. 2006. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl. Acad. Sci. USA 103: 13180-13185.
8. Jakob, T., P. S. Walker, A. M. Krieg, M. C. Udey, and J. C. Vogel. 1998. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J. Immunol. 161: 3042-3049.
9. Tanino, Y., H. Makita, K. Miyamoto, T. Betsuyaku, Y. Ohtsuka, J. Nishihira, and M. Nishimura. 2002. Role of macrophage migration inhibitory factor in bleomycin-induced lung injury and fibrosis in mice. Am. J. Physiol. 283: L156-L162.
10. Liu, Y. Y., W. F. Cai, H. Z. Yang, B. Cui, Z. R. Chen, H. Z. Liu, J. Yan, W. Jin, H. M. Yan, B. M. Xin, et al. 2008. Bacillus Calmette-Guerin and TLR4 agonist prevent cardiovascular hypertrophy and fibrosis by regulating immune microenvironment. J. Immunol. 180: 7349-7357.
11. Razonable, R. R., M. Henault, and C. V. Paya. 2006. Stimulation of toll-like receptor 2 with bleomycin results in cellular activation and secretion of proinflammatory cytokines and chemokines. Toxicol. Appl. Pharmacol. 210: 181-189.
12. Chung, M. P., M. M. Monick, N. Y. Hamzeh, N. S. Butler, L. S. Powers, and G. W. Hunninghake. 2003. Role of repeated lung injury and genetic background in bleomycin-induced fibrosis. Am. J. Respir. Cell Mol. Biol. 29: 375-380.
13. Gold, M. C., M. W. Munks, M. Wagner, C. W. McMahon, A. Kelly, D. G. Kavanagh, M. K. Slifka, U. H. Koszinowski, D. H. Raulet, and A. B. Hill. 2004. Murine cytomegalovirus interference with antigen presentation has little effect on the size or the efector memory phenotype of the CD8 T Cell response. J. Immunol. 172: 6944-6953.
14. Pathak, S. K., S. Basu, K. K. Basu, A. Banerjee, S. Pathak, A. Bhattacharyya, T. Kaisho, M. Kundu, and J. Basu. 2007. Direct extracellular interaction between the early secreted antigen ESAT-6 of Mycobacterium tuberculosis and TLR2 inhibits TLR signaling in macrophages. Nat. Immunol. 8: 610-618.
15. Traidl-Hoffmann, C., V. Mariani, H. Hochrein, K. Karg, H. Wagner, J. Ring, M. J. Mueller, T. Jakob, and H. Behrendt. 2005. Pollen-associated phytoprostanes inhibit dendritic cell interleukin-12 production and augment T helper type 2 cell polarization. J. Exp. Med. 201: 627-636.
16. Reddy, G. K., and C. S. Enwemeka. 1996. A simplified method for the analysis of hydroxyproline in biological tissues. Clin. Biochem. 29: 225-229.
17. Lotze, M. T., and K. J. Tracey. 2005. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5: 331-342.
18. Gauldie, J., P. Bonniaud, P. Sime, K. Ask, and M. Kolb. 2007. TGF-β, Smad3 and the process of progressive fibrosis. Biochem. Soc. Trans. 35: 661-664.
19. Wynn, T. A. 2007. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J. Clin. Invest. 117: 524-529.
20. Chaudhuri, N., S. K. Dower, M. K. B. Whyte, and I. Sabroe. 2005. Toll-like receptors and chronic lung disease. Clin. Sci. 109: 125-133.
21. Kabelitz, D. 2007. Expression and function of Toll-like receptors in T lymphocytes. Curr. Opin. Immunol. 19: 39-45.
22. Amati, L., M. Pepe, M. E. Passeri, M. L. Mastronardi, E. Jirillo, and V. Covelli. 2006. Toll-like receptor signaling mechanisms involved in dendritic cell activation: potential therapeutic control of T cell polarization. Curr. Pharm. Des. 12: 4247-4254.
23. Imanishi, T., H. Hara, S. Suzuki, N. Suzuki, S. Akira, and T. Saito. 2007. Cutting edge: TLR2 directly triggers Th1 effector functions. J. Immunol. 178: 6715-6719.
24. Yang, D., Q. Chen, S. B. Su, P. Zhang, K. Kurosaka, R. R. Caspi, S. M. Michalek, H. F. Rosenberg, N. Zhang, and J. J. Oppenheim. 2008. Eosinophil-derived neurotoxin acts as an alarmin to activate the TLR2-MyD88 signal pathway in dendritic cells and enhances Th2 immune responses. J. Exp. Med. 205: 79-90.
25. Schauber, J., R. A. Dorschner, A. B. Coda, A. S. Buchau, P. T. Liu, D. Kiken, Y. R. Helfrich, S. Kang, H. Z. Elalieh, A. Steinmeyer, et al. 2007. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J. Clin. Invest. 117: 803-811.
26. Guo, H., X. Wu, F.-S. X. Yu, and J. Zhao. 2008. Toll-like receptor 2 mediates the induction of IL-10 in corneal fibroblasts in response to Fusarium solu. Immunol. Cell. Biol. 86: 271-276.
27. Basu, S., and M. J. Fenton. 2004. Toll-like receptors: function and roles in lung disease. Am. J. Physiol. 286: L887-L892.
28. Zhang, X., and D. M. Mosser. 2008. Macrophage activation by endogenous danger signals. J. Pathol. 214: 161-178.
29. Freire-de-Lima, C. G., Y. Q. Xiao, S. J. Gardai, D. L. Bratton, W. P. Schiemann, and P. M. Henson. 2006. Apoptotic cells, through transforming gowth factor-β, coordinately induce anti-inflammatory and suppress pro-inflammatory eicosanoid and NO synthesis in murine macrophages. J. Biol. Chem. 281: 38376-38384.
30. Kim, H. S., M. S. Han, K. W. Chung, S. Kim, E. Kim, M. J. Kim, E. Jang, H. A. Lee, J. Youn, S. Akira, and M.-S. Lee. 2007. Toll-like receptor 2 senses β-cell death and contributes to the initiation of autoimmune diabetes. Immunity 27: 321-333.
31. Girkontaite, I., V. Urbonaviciute, D. Maseda, K. Neubert, M. Herrmann, and R. E. Voll. 2007. Apoptotic cells selectively suppress the Th1 cytokine interferon γ in stimulated human peripheral blood mononuclear cells and shift the Th1/Th2 balance towards Th2. Autoimmunity 40: 327-330.
32. Kaminski, N., J. D. Allard, J. F. Pittet, F. Zuo, M. J. D. Griffiths, D. Morris, X. Huang, D. Sheppard, and R. A. Heller. 2000. Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis. Proc. Natl. Acad. Sci. USA 97: 1778-1783.
33. Estes, J. D., S. Wietgrefe, T. Schacker, P. Southern, G. Beilman, C. Reilly, J. M. Milush, J. D. Lifson, D. L. Sodora, J. V. Carlis, and A. T. Haase. 2007. Simian immunodeficiency virus-induced lymphatic tissue fibrosis is mediated by transforming growth factor β1-positive regulatory T cells and begins in early infection. J. Infect. Dis. 195: 551-561.
34. Tang, Q., and J. A. Bluestone. 2006. Plasmacytoid DCs and Treg cells: casual acquaintance or monogamous relationship? Nat. Immunol. 7: 551-553.
35. + T regulatory cells that modulate pulmonary interstitial fibrosis. J. Immunol. 172: 178-185.
36. Misson, P., S. van den Brule, V. Barbarin, D. Lison, and F. Huaux. 2004. Markers of macrophage differentiation in experimental silicosis. J. Leukocyte Biol. 76: 926-932.
37. Luo, Y., H. Zhou, J. Krueger, C. Kaplan, S.-H. Lee, C. Dolman, D. Markowitz, W. Wu, C. Liu, R. A. Reisfeld, and R. Xiang. 2006. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J. Clin. Invest. 116: 2132-2141.
38. Gorelik, L., and R. A. Flavell. 2002. Transforming growth factor-β in T-cell biology. Nat. Rev. Immunol. 2: 46-53.
39. Yu, H., M. Kortylewski, and D. Pardoll. 2007. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7: 41-51.
40. Welte, T., S. S. M. Zhang, T. Wang, Z. Zhang, D. G. T. Hesslein, Z. Yin, A. Kano, Y. Iwamoto, E. Li, J. E. Craft, et al. 2003. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc. Natl. Acad. Sci. USA 100: 1879-1884.
41. Ogata, H., T. Chinen, T. Yoshida, I. Kinjyo, G. Takaesu, H. Shiraishi, M. Iida, T. Kobayashi, and A. Yoshimura. 2006. Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-β1 production. Oncogene 25: 2520-2530.